 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ALVR106 / AlloVir, Baylor College of Medicine
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=16, Terminated, Sponsor: AlloVir
N=77 --> 16 | Trial completion date: Jun 2024 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Jan 2024; Strategic sponsor decision
- ALVR106 / AlloVir, Baylor College of Medicine
ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial (216 (Meeting Level, Henry B. Gonzalez Convention Center); in-person) - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_750;
N=77 --> 16 | Trial completion date: Jun 2024 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Jan 2024; Strategic sponsor decision ALVR106 was safe and well tolerated, supporting its continued evaluation in HCT and SOT recipients.
- ||| ALVR106 / AlloVir, Baylor College of Medicine
Enrollment open, Trial initiation date: Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant (clinicaltrials.gov) - Apr 19, 2022
P1/2, N=77, Recruiting, Sponsor: AlloVir
ALVR106 was safe and well tolerated, supporting its continued evaluation in HCT and SOT recipients. Not yet recruiting --> Recruiting | Initiation date: Oct 2021 --> Mar 2022
- |||| ALVR106 / AlloVir, Baylor College of Medicine
New P1/2 trial: Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant (clinicaltrials.gov) - Jun 22, 2021
P1/2, N=77, Not yet recruiting, Sponsor: AlloVir